


12-04-01

CASE 430724ADC1

RECEIVED
U.S. PATENT AND TRADEMARK OFFICE
TECH CENTER 1600/2900 #6
OCT 26 2001
GARRETT JEL
3/19/02



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL813100446US
Express Mail Label Number

October 24, 2001
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**IN RE APPLICATION OF
KRIWET ET AL.**

Art Unit: 1614
Examiner: V. Kim

APPLICATION NO: 09/871,367

FILED: MAY 31, 2001

FOR: TOPICAL COMPOSITIONS COMPRISING ASCOMYCINS

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449. Some of the listed references were cited in a search report in a corresponding International application. Copies of these references and the search report are enclosed herewith. Also, copies of the other cited references are enclosed herewith.

The *Dermatika* reference is cited in the specification at page 4, first full paragraph, as providing a description of suitable moisturizers.

Fiedler, H.P. "Lexikon der Hfsstoffe für Pharmazie, Kosmetik und angrenzende Gebiete" is a German book on excipients wherein, e.g., general properties, characteristics, sometimes suppliers, are given. The specific pages (p. 720; p. 1013-1017; p. 1303) mentioned on page 4 of the specification provide specifics on glycolic acid, lactic acid, and 2-pyrrolidone-5-carboxylic acid respectively. On page 5 of the specification, the citation is relevant in relation to Plastibase(R).

The "Gelbe Liste" gives examples of creams, gels and ointments against psoriasis comprising e.g. vaseline, paraffin or urea. The information given includes: composition (Zusammensetzung), use (Anwendung), contra-indications (Gegenanzeigen), pregnancy (Schwangerschaft), nursing (Stillzeit), side effects (Nebenwirkungen), intercations (Wechselwirkungen), dosage (Dosierung), warnings (Warnhinweise). None of the compositions comprises ascomycin (ASM).

Applicant's direct the Examiner's attention to co-pending U.S. Patent Application Serial Nos. 09/668,677 and 09/738,104 that may be relevant to the present application.

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis Corporation.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,


Carol A. Loeschorn
Carol A. Loeschorn
Attorney for Applicants
Reg. No. 35,590

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6932

Date: October 24, 2001

Encls: Additional copy of this paper
PTO Form 1449 (4 pages)
58 References